Individualized outcome prediction classifiers were successfully constructed through expression profiling of a total of 8644 genes in 50 non-small-cell lung cancer (NSCLC) cases, which had been consecutively operated on within a defined short period of time and followed up for more than 5 years. The resultant classifier of NSCLCs yielded 82% accuracy for forecasting survival or death 5 years after surgery of a given patient. In addition, since two major histologic classes may differ in terms of outcome-related expression signatures, histologic-type-specific outcome classifiers were also constructed. The resultant highly predictive classifiers, designed specifically for nonsquamous cell carcinomas, showed a prediction accuracy of more than 90% independent of disease stage. In addition to the presence of heterogeneities in adenocarcinomas, our unsupervised hierarchical clustering analysis revealed for the first time the existence of clinicopathologically relevant subclasses of squamous cell carcinomas with marked differences in their invasive growth and prognosis. This finding clearly suggests that NSCLCs comprise distinct subclasses with considerable heterogeneities even within one histologic type. Overall, these findings should advance not only our understanding of the biology of lung cancer but also our ability to individualize postoperative therapies based on the predicted outcome.
Introduction
Lung cancer is the most prevalent and deadly cancer in economically developed countries. In the US, more than 170 000 people die annually due to lung cancer, while Japan is facing a continuing and steep increase in lung cancer deaths with loss of more than 51 000 lives annually. Lung cancers are classified into two major groups, small-cell lung cancer and non-small-cell lung cancer (NSCLC), based on their clinicopathologic characteristics. Owing to the considerable differences in their etiologies, genetic and epigenetic changes and clinicopathologic features, NSCLCs are often further subgrouped into two major categories, that is, squamous cell carcinomas and nonsquamous cell carcinomas (Minna et al., 1997; Osada and Takahashi, 2002) .
Surgical resection gives the best hope for a cure for NSCLC cases, which comprise 80-85% of lung cancers. Unfortunately, however, their long-term survival rate remains unsatisfactory and no more than 50% of the cases that have successfully undergone potentially curative resection can survive for 5 years after operation. The TNM classification according to tumor size, extent of nodal involvement and the presence or absence of distant metastasis is routinely used as a prognostic tool, but it only provides information about what percentage of cases at a particular disease stage, which a given patient belongs to, can be expected to be alive at specific postoperative time points. Although various genetic and epigenetic changes of cancer-related genes have been identified and examined in the search for clinically relevant prognosticators, no single variable thus far evaluated has proven to be sufficiently predictive to accurately forecast a patient's outcome (Slebos et al., 1990; Horio et al., 1993; Mitsudomi et al., 2000) .
Recent rapid progress in microarray technology has made it possible to analyse gene expression profiles on a genome-wide basis in order to search for molecular markers for cancer classification and outcome prediction (Golub et al., 1999; Alizadeh et al., 2000; Perou et al., 2000; Khan et al., 2001; Pomeroy et al., 2002; Ye et al., 2003) . While lung cancers are known to be very heterogeneous in various aspects as clearly mentioned, recent expression profiling studies have shown the presence of several subclasses with distinct expression profiles not only among NSCLC but also and specifically among adenocarcinoma (Bhattacharjee et al., 2001; Garber et al., 2001; Beer et al., 2002; Virtanen et al., 2002) . However, the existence of clinically relevant subclasses of squamous cell carcinomas in terms of expression profiles has not been detected thus far, while development of an individualized outcome classifier is eagerly awaited in the hope of implementing tailor-made treatments for this fatal disease.
In the study presented here, a consecutively operated, well-defined cohort of 50 NSCLC cases, followed up for more than 5 years, was used to acquire expression profiles of a total of 8644 unique genes, leading to the successful construction of supervised learning methodbased individualized outcome prediction classifiers with high accuracy. In addition, the identification by means of unsupervised hierarchical clustering analysis of two distinct subclasses of squamous cell carcinomas with interesting histologic distinctions and a significant difference in their prognosis is also reported.
Results

Unsupervised hierarchical clustering of NSCLCs
We first applied unsupervised hierarchical clustering algorithm to a comparison of gene expression profiles of 50 NSCLC cases using the filtered 900 spots corresponding to 829 unique genes that had passed our filtering procedures. The resulting clusters recapitulated the distinctions between well-established histologic classes of NSCLCs, that is, squamous cell and nonsquamous cell carcinomas (Figures 1a-f) , and the results of immunohistochemical analysis of TTF-1 and cytokeratin 7 (KRT7) expression, which used tissue microarrays containing all of the cases examined in this study, were consistent with those of the cDNA microarray analysis (data not shown). We noted that squamous cell carcinomas formed a more discrete cluster than nonsquamous cell carcinomas, demonstrating the generally strong expression of several well-accepted differentiation markers of squamous epithelium including cytokeratins 5 and 13, S100A2 and galectin 7 (LGALS7) (Figure 1d ) (Magnaldo et al., 1998; Chu and Weiss, 2002) . Markedly high-level expression of small prolinerich proteins such as SPRR1B and SPRR2C was also generally observed in squamous cell carcinomas (Hu et al., 1998) . While squamous cell carcinomas were clustered as a large single cluster, there appeared to be two major subclasses of squamous cell carcinomas in relation to the gene expression profiles, and the distinctions between the two subclasses could be even more clearly illustrated in the separate hierarchical clustering analysis of squamous cell carcinomas (data not shown). Squamous cell carcinoma cluster 1 (SQ1) expressed a characteristic set of genes that are related to extracellular matrix proteins, including fibronectin and various collagen subunits such as a2(I) and a1(III) (Figure 1f ), as well as those related to DNA replication and cell proliferation including ARAF1 and EPHA1 (Figure 1e ) (Shelton et al., 2003; Walker-Daniels et al., 2003) . Interestingly, patients belonging to the SQ1 cluster had a significantly poorer prognosis after potentially curative resection than those of SQ2 (Figure 2a , P ¼ 0.013 by log-rank test). Another prominent distinction between SQ1 and SQ2 was their growth patterns. Seven of the eight (88%) cases of SQ1 showed an infiltrative growth pattern with dense fibrous stroma in contrast to lack of these features in six of the seven SQ2 tumors (P ¼ 0.010 by Fisher's exact test), which showed a rather well-circumscribed, expansive growth pattern with inconspicuous keratinization (Figure 2b ).
Adenocarcinomas, a major fraction of nonsquamous cell carcinomas, also appeared to be subclassifiable into two major groups according to their expression profiles: adenocarcinoma cluster 1 (AD1) clustered together with squamous cell carcinomas, and AD2, 3 and 4, which formed another distinct cluster. Of the latter subclass, AD3 most typically showed strong expression of peripheral lung cell markers including TTF-1 (TITF1), SP-C (SFTPC) and SP-A (SERPA2) (Figure 1b ) (Yatabe et al., 2002) . Patients belonging to the AD3 cluster were predominantly female nonsmokers with a well-differentiated adenocarcinoma. In addition, 80% (eight of 10) of the AD3 cases were female subjects in contrast to 29% (six of 21) in non-AD3 adenocarcinoma clusters (P ¼ 0.018, Fisher's exact test), while welldifferentiated tumors were more frequent in AD3 (60%) cases than other adenocarcinoma clusters (14%) (P ¼ 0.015 by Fisher's exact test). A total of 70% of the AD3 cases were found to be nonsmokers, and this ratio was considerably higher than that for non-AD3 clusters (38%), which in fact contained significantly more heavy smokers (420 pack years) than AD3 (P ¼ 0.046 by Fisher's exact test). In marked contrast, AD1 showed low-level expression of peripheral lung markers such as TTF-1 and SP-C and to some extent shared gene expression profiles with squamous cell carcinomas, although they were still clearly distinct. Tumors corresponding to AD2 characteristically showed a strong expression of a number of expressed sequence tags (ESTs), whereas expression of the same set of ESTs was found to be distinctly reduced in AD4 as well as SQ1, suggesting that characterization of these ESTs may shed light on the biology of these tumor subclasses (Figure 1c ).
Construction of a survival prediction model for NSCLCs
In order to develop an individualized outcome prediction classifier, we used a signal-to-noise metric first to select genes that most clearly distinguished prognosisfavorable from fatal patients. The unsupervised hierarchical clustering algorithm using the top 100 spots corresponding to 98 unique genes yielded two major branches representing those with favorable and fatal prognosis (Figure 3a) . Of the 21 patients in the left or 'favorable' branch, 19 had survived 5 years after surgery, while 15 of the 29 cases in the right or 'fatal' branch had died within 5 years after surgery. Their Kaplan-Meier survival curves showed a statistically significant difference (Figure 3b , P ¼ 0.0025, log-rank test).
Since the ultimate aim was the development of an individualized outcome prediction classifier, we next applied a supervised learning method. To this purpose, a weighted-voting outcome classifier was constructed based on the predictive genes, which were preselected using a signal-to-noise metric. The learning errors for Profile-based outcome prediction for lung cancer S Tomida et al each model, to which increasing numbers of the preselected predictive genes were applied, calculated with the leave-one-out cross-validation method. The weighted-voting model using 25 predictive genes showed the highest accuracy for the prediction of an individual's outcome (Figure 4a ), that is, in 41 of 50 (82%) cases. The 25 genes used for constructing the outcome classifier of NSCLCs are listed in Table 1 . With this classifier, 27 of 33 (82%) cases, who actually had survived longer than 5 years after surgery, were judged to have a 'favorable' prognosis, while 14 of the 17 (82%) patients who had died within 5 years were correctly predicted as having a 'fatal' outcome ( Figure 4b ). Survival curves of the patients with 'favorable' and 'fatal' predictions are plotted in Figure 4c , showing a significant difference between the groups (P ¼ 6.0 Â 10 À6 ). We also employed other supervised learning algorithms, including the support vector machine and k-nearest neighbors, using increasing numbers of genes as mentioned above. Although accuracies of these models were comparable to that of the weighted-voting outcome classifier, the latter achieved the highest accuracy (data not shown).
Construction of the survival prediction models specific for squamous or nonsquamous cell carcinoma cases
It is generally accepted that squamous cell and nonsquamous cell carcinomas are distinct disease entities in terms of their clinicopathologic features as well as their etiologies (Minna et al., 1997; Osada and Takahashi, 2002) . This concept has been supported by the presence of clearly discriminating expression profiles for these two tumor types (Bhattacharjee et al., 2001; Garber et al., 2001; Kikuchi et al., 2003) . We therefore constructed outcome prediction classifiers specific for each tumor subtype by using the weighted-voting algorithm and the predictive genes for each subtype selected by signal-to-noise metric. Leave-one-out crossvalidation of the classifiers with increasing numbers of Tumors belonging to the SQ1 cluster frequently exhibited invasive growth to surrounding normal lung tissues with active stromal reaction (SQ1-i), while prominent keratinization was a characteristic of SQ1 (SQ1-ii). Tumors of the SQ2 cluster were generally well circumscribed due to their expansive growth (SQ2-i), and minimal stromal reaction is observed in this type. In addition, keratinization and nuclear pleomorphisms were inconspicuous in tumors of SQ2 (SQ2-ii) Figure 3 Unsupervised hierarchical clustering of 50 NSCLCs according to the expression of top 100 genes by signal-to-noise metric, which distinguish fatal and favorable prognosis. (a) Twodimensional hierarchical with the top 100 predictive genes. (b) Kaplan-Meier survival curves for favorable versus fatal groups of 50 samples characterized by hierarchical clustering using the top 100 predictive genes Profile-based outcome prediction for lung cancer S Tomida et al the higher-ranked predictive genes yielded the highest accuracies with 12 genes for nonsquamous and 19 genes for squamous cell carcinomas (Tables 2 and 3) . Results showed that patients' outcome 5 years after surgery were correctly predicted for 31 of 34 (91%) nonsquamous cell carcinoma cases (Figure 5a ). Of the 25 cases judged as having 'favorable' prognosis, 23 (92%) had indeed survived 5 years after surgery, whereas only one of nine (11%) patients predicted as being 'fatal' had survived for 5 years. The differences between survival curves of the 25 patients with the 'favorable' and the nine cases with the 'fatal' prediction were highly significant ( Figure 5b , P ¼ 2.4 Â 10
À7
). In the case of squamous cell carcinomas, the weightedvoting model successfully predicted 5-year outcome for 15 of 16 (94%) patients (Figure 5c ). Eight of eight (100%) samples judged as being 'favorable' had survived 5 years after surgery, while seven of eight (88%) samples predicted as being 'fatal' had actually died within 5 years. Survival curves based on these predictions showed highly significant differences between the favorable and fatal groups ( Figure 5d , P ¼ 3.3 Â 10 À5 ). It was noted that the 12 and 19 genes, which were used to construct the respective outcome classifiers for nonsquamous and squamous cell carcinomas, did not show any overlaps, and histologic-type-specific outcome classifiers contained only two genes each of the top 100, signal-to-noise-preselected genes of the other type of NSCLCs.
Confirmation of the robustness of the classifiers by using an independent blinded validation dataset as well as by random permutation tests
To validate the prognosis classifiers described here, we analysed an additional independent set of six NSCLC cases, three nonsquamous and squamous cell carcinomas each, in a completely blinded fashion. The outcome classifier for both types of NSCLCs correctly predicted the disease outcome in five of the six cases, including the death of a patient with a stage I tumor (Figure 4b ). The outcome classifier for nonsquamous cell carcinomas accurately predicted both deaths and one survival (Figure 5a ). The outcome classifier for squamous cell carcinomas correctly predicted the outcome for one of the three cases (Figure 5c ).
We also performed permutation tests to determine whether the gene sets used in the outcome classifiers were robust, and found highly significant results (Po0.0001 in all three classifiers). Through permutation tests analysing 10 000 datasets with permutated class labels, it was shown that outcome classifiers performing with equal or higher accuracy for the initial dataset as well as for the validation dataset could not be obtained by chance association in either NSCLCs (P ¼ 0.0104) or in nonsquamous cell carcinomas (P ¼ 0.0055). This type of estimate, however, did not support the statistical significance of the results obtained with squamous cell carcinoma classifier. Since survival or death is a matter of all or nothing, currently available information regarding what percentage of those at a certain disease stage are likely to survive after a certain period of time is insufficient in many respects. The study presented here described the successful construction of individualized outcome classifiers as a result of using the gene expression profiling data-and weighted-voting algorithm-based approach, which allowed us to predict outcomes for surgically treated lung cancer patients on an individual basis. Although our outcome classifiers were constructed by using a modestly sized cohort, highly robust prediction models were obtained especially for the prediction of outcome for nonsquamous cell carcinomas, which constitute about 60% of NSCLCs. In fact, patients' 5-year postoperative survival status was correctly predicted for 91% of the leave-one-out cross-validation *P-values were assigned based upon the frequency, with which signal-to-noise statistics, which were calculated for the 10 000 permutations of the sample labels in each of the nonsquamous cell and squamous cell carcinoma datasets, yielded better results than the actual signal-to-noise statistic.
a Ranking of the signal-to-noise statistics for the genes in the nonsquamous cell and squamous cell carcinoma datasets *P-values were assigned based upon the frequency, with which signal-to-noise statistics, which were calculated for the 10 000 permutations of the sample labels in the nonsquamous cell carcinoma dataset, yielded better results than the actual signal-to-noise statistic. a Ranking of the signal-tonoise statistics for the genes in the squamous cell carcinoma dataset Profile-based outcome prediction for lung cancer S Tomida et al dataset, and this prediction accuracy was confirmed for the independent validation dataset. It should be noted that the outcome classifier appeared to perform well independently of disease stage; among 24 stage I/II nonsquamous cell carcinoma cases, 17 survivals and five deaths were correctly predicted with just a single misclassification for each, while accurate prediction was also obtained for nine of the 10 stage III cases. Beer et al. (2002) recently described a prediction model, which classifies adenocarcinoma cases into high-and low-risk groups, although their model was not intended to predict 5-year survival for individual cases. The difference in 5-year survival between the high-and lowrisk groups can be estimated as 40% based on the Kaplan-Meier survival curves shown in Figure 3d , whereas our nonsquamous cell carcinoma outcome classifier yielded an 81% difference in 5-year survival between the fatal and favorable classifications (Figure 5b ). At present, intensive chemotherapy is given only to patients with an advanced metastatic disease. However, the development of highly accurate, individualized outcome classifiers should make it possible to select patients, who are at high risk of future failure and thus most eligible for such intensive adjuvant therapy with the intention of eradicating undetectable micrometastases, sources of future recurrence.
The gene sets used for the outcome classifiers contained various functionally relevant genes (Table 1) . For example, MYC and FOSL1 are known to be involved in the process of cellular transformation (Vennstrom et al., 1982; Mechta et al., 1997) . The MYC oncogene, frequently overexpressed with or without amplification in lung cancers, is associated with a poor prognosis (Johnson et al., 1987) , as is SERPINE1. (Robert et al., 1999) FOSL1 has been shown to play a role as a predominant component of the AP-1 complex in ras-induced transformation (Mechta et al., 1997), and it also mediates induction of SPRR1B in response to epithelial injury caused by a variety of carcinogens (Patterson et al., 2001; Vuong et al., 2002) . Both COPB and ARCN1 constitute COPI-coated vesicles and are involved in the transport of G protein-coupled receptors, while the binding of Ras-related GTP-binding protein Cdc42 to another COPI subunit, COPG, has been shown to be important for transmitting transforming signals (Wu et al., 2000) . PTN and MST1 are ligands of tyrosine kinase receptors, while it has been suggested that MST1 and its receptor RON form an autocrine/ paracrine system involved in cell migration of NSCLC cells (Willett et al., 1998) . CCT3 and ACTR3 may also be involved in motile and invasive features, since ACTR3 is a major constituent of the ARP2/3 complex required for protrusion of the lamellipodia (Craig and Chen, 2003) , while CCT3 is involved in actin and tubulin folding (Martin-Benito et al., 2002) . Increased WEE1 expression in patients with fatal outcome may be a reflection of higher proliferative activity. In this connection, high-level expression of WEE1 in combination with the Cyclin and CDK genes has been reported in hepatocellular carcinoma (Masaki et al., 2003) . Ramaswamy et al. (2003) recently suggested the presence of a metastatic signature based on their analysis of lung adenocarcinoma cases and identification of a 17-gene set associated with metastatic capability. It is interesting to note that two closely related genes, that is, members of the actin and small nuclear ribonucleoprotein families, are included as predictors of concordant directions in both the 12-gene set of our nonsquamous cell carcinoma outcome classifier and their 17-gene set predicting metastasis of adenocarcinomas (Tables 2 and 3 ). In addition to SNRPB, three other genes (EIF4A1, EIF2S2 and HNRPA1) involved in translation apparatus are also included as fatal outcome predictors in our list of top 100 genes, while *P-values were assigned based upon the frequency, with which the signal-to-noise statistics, which were calculated for the 10 000 permutations of the sample labels of the squamous cell carcinoma dataset, yielded better results than the actual signal-to-noise statistic.
a Ranking of the signal-tonoise statistics for the genes in the nonsquamous cell carcinoma dataset Profile-based outcome prediction for lung cancer S Tomida et al Ramaswamy et al.'s 17-gene set contained two functionally related genes, EIF4EL3 and HNRPAB, suggesting the involvement of their upregulation in tumor progression. Moreover, HLA class II genes are included in both gene sets as favorable predictors. Although the use of different array platforms makes it difficult to evaluate frequencies of overlap of the selected genes in the present study and others, it is interesting that four of the five genes, which are shared by the top 100 genes of the Michigan group (Beer et al., 2002) and ours, appear to be predictive in the same direction. The outcome classifiers described here were constructed with a relatively modest number of cases, but the use of nonbiased, consecutive cases collected within a short period of time with complete follow-up data may have been a factor in their high accuracy, especially of the outcome classifier for nonsquamous cell carcinomas. This needs to be confirmed, however, in a large, independent cohort of patients, preferably in a prospective manner, before these classifiers can be put to clinical use for the selection of candidates for intensive adjuvant therapies. Nevertheless, the strategy presented here appears to be promising, and suggests that it may also be possible to develop similar predictive classifiers for predicting patients' response to conventional chemotherapy and/or molecular-targeted therapeutics such as those recently introduced involving EGF receptor inhibition. In the future, lung cancer patients who are classified as having fatal but therapeutic agent-responsive expression signatures can be expected to be selectively and intensively treated with the most appropriate active agents in an individualized manner, ultimately leading to significant improvement in the present dismal survival rate.
Our unsupervised hierarchical clustering analysis underscores previous observations that adenocarcinomas and squamous cell carcinomas are very distinct in terms of gene expression profiles (Bhattacharjee et al., 2001; Garber et al., 2001; Virtanen et al., 2002; Kikuchi et al., 2003) . In addition, we observed that genes useful for constructing nonsquamous cell and squamous cell carcinoma outcome classifiers did not show any overlap, providing further support to the notion of two distinct entities. Interestingly, the unsupervised hierarchical clustering analysis used in our study demonstrated for the first time the existence of two clinically relevant subsets of squamous cell carcinomas with distinct gene expression signatures and markedly different clinicopathologic features. SQ1 showed a characteristic invasive growth pattern and a significantly worse prognosis than SQ2 (Figure 2) . The most noticeable feature of the expression signature of SQ1 was high-level expression of extracellular matrix proteins, including fibronectin, SPARC and various collagen subunits such as a2(I) and a1(III) (Figure 1f) . By using an expression profiling analysis of a in vivo-selected, highly metastatic melanoma model, Clark et al. (2000) found that enhanced expression of genes involved in the extracellular matrix assembly, including fibronectin, collagen a2(I) and a1(III), was associated with the acquisition of a metastatic phenotype during the in vivo selection, a finding consistent with the invasive growth pattern and poor prognosis of SQ1 in our study. Ramaswamy et al. (2003) also found a similar association between metastatic potential and collagen gene expression in the molecular signature analysis of solid tumors. In addition, expression of a set of ESTs was found to be distinctly reduced in SQ1 when compared with SQ2 (Figure 1c) , suggesting that the reduced expression of genes corresponding to these ESTs may be related to the aggressive nature of SQ1. Although the gene expression-based subclasses of squamous cell carcinomas were identified by using a small cohort of squamous cell carcinomas, the present findings warrant further validation and characterization. Figure 5 Results of histologic-type-specific outcome classification of nonsquamous cell and squamous cell lung cancers. The weighted-voting supervised learning was conducted using histologic-type-specific sets of genes preselected with the signal-to-noise metric. Circles and triangles indicate the same items as those in In view of their distinct molecular signatures, the existence of a few subclasses of adenocarcinomas has been reported (Bhattacharjee et al., 2001; Garber et al., 2001; Beer et al., 2002; Virtanen et al., 2002) , although the expression signatures identified in these studies did not show complete correspondence with each other or with those identified by us. However, there is a high degree of consistency in the fact that all these studies have identified a subset of adenocarcinomas with a highlevel expression of genes related to differentiation of normal peripheral lung epithelial cells such as TTF-1 and SP-C. This subclass of adenocarcinomas is most typically represented by AD3 in our study, which appears to correspond to AD group 2 in the Stanford study and to C4 in the MIT study. Consistently notable features of this subclass are significantly higher proportions of females, non/light smokers and well-differentiated tumors. These findings are consistent with our previous observations that there is a subset of adenocarcinomas which may represent those arising from cells committed to become peripheral lung epithelial cells under weaker influence of smoking (Yatabe et al., 2002) .
In conclusion, we have been successfully constructing an individualized outcome prediction classifier, which appears to be useful especially for nonsquamous cell carcinomas. In addition, we have been able to demonstrate the presence of marked heterogeneities of NSCLCs by identifying clinically relevant subclasses not only for adenocarcinomas but also for squamous cell carcinomas. Further studies appear to be warranted on the basis of these findings, with the aim to improve both understanding and survival of this fatal disease.
Materials and methods
Tissue sample
A total of 50 NSCLC tissue specimens (30 adenocarcinomas, 16 squamous cell carcinomas and four large cell carcinomas) were obtained from 15 female and 35 male patients, who had consecutively undergone potentially curative resection at Aichi Cancer Center Hospital (Nagoya, Japan). The vast majority of these lung cancer specimens were acquired within an 11-month period between December 1995 and October 1996, while squamous cell and large cell carcinomas were also obtained during an additional few months around this period of time. An additional three cases each of adenocarcinomas and squamous cell carcinomas, which were collected just before or after the specimen collection period, were used for an independent validation dataset. The tumor specimens were embedded in OCT compound and stored at À801C until use with the approval of the institutional review board. The median age of this cohort was 63 (range: 43-76), and there were 23 pStage I tumors, 11 pStage II, and 16 pStage III. Approvals for this study were obtained from the institutional review board of the Aichi Cancer Center.
RNA extraction and microdissection
On average, 50 7 mm-thick cryostat sections were prepared for the extraction of total RNA from tumor cell-rich areas, which were identified by a surgical pathologist (YY) using every 10th section stained by May-Giemsa. Careful attention was paid to the microdissection of only such tumor cell-rich areas, yielding an average of 75.4% tumor cell content (Figure 1i ). RNAs were then isolated using RNAeasy (Quiagen, Valencia, CA, USA) according to the manufacturer's instruction, and their quality was checked with the RNA 6000 Nano Assay kit and the 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA).
Microarray experiments and acquisition of datasets
We used two sets of membrane cDNA microarrays (GeneFilter Human Microarrays Release I and Release II; Invitrogen, Carlsbad, CA, USA), which contained a total of 11 168 spots corresponding to 8644 independent genes. A measure of 5 mg of total RNA was reverse-transcribed using oligo-dT primers (Invitrogen) and SuperScript II reverse transcriptase (Invitrogen) in the presence of 100 mCi of [ 33 P]dCTP (Amersham Bioscience, Piscataway, NJ, USA) according to the instructions for the GeneFilters (Invitrogen) with slight modification. The GeneFilters were prehybridized for 2 h at 511C with 0.5 mg/ml of poly-dA (Invitrogen) and 0.5 mg/ml Cot-1 DNA (Invitrogen) in 10 ml of AlkPhos DIRECT hybridization buffer (Amersham Bioscience) and then hybridized for 17 h at 511C with the denatured radiolabeled probe. Hybridization of the arrays was followed by two washings with a solution containing 2 M of urea, 0.1 % of SDS, 50 mM of Na phosphate buffer (pH 7.0), 150 mM of NaCl, 1 mM of MgCl 2 and 0.2% of AlkPhos DIRECT blocking reagent (Amersham Bioscience). The arrays were then washed twice with a solution containing 2 mM of MgCl 2 , 50 mM of Tris and 100 mM of NaCl, and with a solution containing 2 mM of MgCl 2 , 50 mM of Tris and 15 mM of NaCl. All procedures were carried out with the aid of custom-made AutoHybridizers (Fuji Photo Film, Tokyo, Japan). The arrays were then exposed for 2 h to an Imaging Plate and scanned at 25-mm resolution with a BAS5000 phosphoimager (Fuji Photo Film), images of the hybridized arrays were processed with L Process (Fuji Photo Film) and signal intensities quantified with ArrayGauge software (Fuji Photo Film). After each hybridization, the arrays were stripped by boiling them in 0.5% SDS solution for 60 min and scanned for residual hybridization before the next round of hybridization with a newly labeled probe of the same sample to acquire their expression profiles in duplicate.
Data rescaling and preprocessing
The raw data were rescaled to account for the differences in individual hybridization intensities. We employed a rankinvariant scaling method to select genes (Tseng et al., 2001) , which were then used for fitting of a nonlinear normalization curve. After normalization, scatter plots of the 50 pairs of replicate data points for each of the genes were generated, the reproducibility of expression between the replicate pairs was assessed, and genes showing a Pearson correlation coefficient higher than 0.85 were selected. Averaged values of the first and the second hybridizations were used for further analyses. In addition, genes whose expression levels did not vary by a factor of at least 2 across the 50 samples were eliminated, because they were unlikely to be informative. Genes with a median intensity lower than 0.3 were also filtered out from the following analyses.
Hierarchical clustering and construction of outcome classifiers
Average linkage hierarchical clustering was performed by using the Cluster program following log transformation and median centering, and the results were visualized using the TreeView program (Eisen et al., 1998) . Predictive genes that most effectively distinguished prognosis-favorable patients Profile-based outcome prediction for lung cancer S Tomida et al from those with fatal outcome were selected by means of signal-to-noise metrics (Golub et al., 1999) . Briefly, when prognosis-favorable and fatal patients are defined as class 0 and 1, signal-to-noise statistic (S x ) is calculated as S x ¼ (m class0 Àm class1 /s class0 þ s class1 ), where, for each gene, m class0 represents the mean value and s class0 represents the standard deviation for that gene in all samples of class 0. We selected top-ranked genes based on the absolute values for S x of each gene. A weighted-voting classification algorithm was employed to predict outcome by using the genes selected as described above and the resulting outcome classifiers were tested by means of 'leave-one-out' cross-validation (Golub et al., 1999) . In this scheme, the algorithm can also be used to find the decision boundaries between the class means: b x ¼ (m class0 þ m class1 )/2 for each gene in addition to computing S x . To predict the class of a test sample g, each gene x in the predictive gene set has a vote based on the expression in this sample (g x   g ) and b x : V x ¼ S x (g x g Àb x ) and the final vote for class 0 or 1 is sign ( P x V x ). The votes were summed to determine the winning class, as well as a 'prediction strength' (PS), which is a measure of the margin of victory that ranges from 0 to 1. The PS is defined as PS ¼ (V win ÀV lose )/ (V win þ V lose ), where V win and V lose are the total votes for the winning and losing classes. The measure PS reflects the relative margin of victory of the vote.
Permutation tests
For the permutation tests of statistical significance of classspecific markers, 10 000 random permutations of the sample labels (dead or alive) were performed with the dataset, and the signal-to-noise ratio was recalculated for each gene and for each class label permutation. Each gene was thus assigned a P-value based upon the frequency by which the permutated signal-to-noise statistics were better than the actual signal-tonoise ratio.
A total of 10 000 random sets of genes of the same numbers used for the actual outcome classifiers were generated from the pool of 900 informative genes, and each of these permuted gene sets was then used for prediction with an independent weighted-voting algorithm by using the leave-one-out cross validation strategy. The P-values for each outcome classifier were assigned based on the frequency (N) with which random models performed better than models generated by using the significant genes selected by signal-to-noise, or P ¼ N/10000. The probability that outcome classifiers constructed by chance might outperform the actual classifiers was also examined. In this test, the outcome labels were randomly permutated 10 000 times and for each instance, a set of models was built by using the same set of parameters, for example, the number of predictive genes, as the ones used for finding the actual outcome classifiers. The probabilities of chance construction were calculated based on the frequencies with which random models performed better than the actual models in leave-oneout cross-validation as well as in further validation with independent datasets.
